Swiss pharmaceutical firm lets dogs die cruel death
Dogs are being left to die in agony in Germany after lab testing for the Swiss pharma company Inthera Bioscience, reports Swiss public television, SRF.
The dogs are young beagles, who are given high doses of substances for experiments on behalf of the Swiss biotech company, according to SRF. They are then left to die in agony with no care.
The report carries disturbing photos by an employee of the animal protection organisation Soko Tierschutz. This employee got himself hired as a carer in the LPTExternal link animal testing laboratory in Hamburg, and documented for several months what was happening there, says the report.
The pictures show tubes being inserted into a dog’s stomach and a test substance injected to find the dose at which severe side effects including death occur. The scenes show how the dogs suffer unnecessarily before their death, as they are left to die in agony.
SRF says that the laboratory is violating international welfare regulations and that such proceedings would not be permitted in Switzerland.
It quotes Friedrich Mülln of Soko Tierschutz as saying that such experiments are easier to carry out in Germany. “It is cheaper and the authorisation is simpler,” he says.
Asked for a response, Swiss firm Inthera Bioscience wrote that the authorities have approved all tests but that the company would suspend further cooperation with the service provider, LPT, until it had a “clear picture of the situation”.
LPT declined to answer specific questions but said such experiments were within the law and that its treatment of animals had never been questioned. An investigation into the service provider’s practices has been opened by the competent authorities following these findings, says SRF.
More
More
Stats show fewer animal experiments
This content was published on
Animal testing dropped by around 5% in 2018, latest figures show.
Swisscom receives greenlight for acquisition of Vodafone Italia
This content was published on
The takeover of Vodafone Italia by Swisscom is nearing completion. All relevant authorities have now approved the €8 billion (CHF7.45 billion) deal.
Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed
This content was published on
The Danish pharmaceutical giant, Novo Nordisk, faced setbacks on Friday that weighed on the share price of Swiss injection device manufacturer Ypsomed.
Swiss press react to EU deal with mix of euphoria and scepticism
This content was published on
Swiss media reaction to the agreement between Switzerland and the EU varies widely. Some are celebrating, while others worry about what is to come.
Swiss Solidarity donations to tackle child abuse top CHF4 million
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has raised over CHF4 million ($4.3 million) to tackle child abuse.
EU Commission president says Swiss-EU deal is ‘historic’ agreement
This content was published on
At a joint media conference with Swiss President Viola Amherd in Bern, European Commission President Ursula von der Leyen spoke of a "day of joy".
Switzerland and EU reach deal on future bilateral relations
This content was published on
Switzerland and the European Union have announced a political agreement to update their trading relationship after almost a decade of difficult talks.
Should journalists be more critical of research involving animals?
This content was published on
An anti-animal testing advocate and a science journalist address the Swiss media’s role in the debate over research involving animals.
This content was published on
The Swiss authorities have registered a major increase in militant animal rights activities last year, according to a newspaper report.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.